Leaderboard

En | De
Sie sind hier: Onkologie » Urologische Tumoren 16. Mai 2026
Suchen
medline.ch
Urologische Tumoren
Erweiterte Suche
Dermatologie
Endokrinologie
Ernährung
Gastroenterologie
Gynäkologie
Hämatologie
Infektiologie
Kardiovaskuläre Erkrankungen
Muskuloskelettale Erkrankungen
Neurologie
Onkologie
Bewegungsapparat
Blut
Endokrine Organe
Gynäkologische Tumoren
Haut
Magen-Darm
ORL
Respirationstrakt
Urologische Tumoren
ZNS
Ophthalmologie
ORL
Pädiatrie
Psychiatrie
Respirationstrakt
Sportmedizin
Urologie-Nephrologie
Schrift: Schrift grösser Schrift kleiner

Rect Top
   Seite 1 von 8914  vorhergehende Seite nächste Seite
   
   Artikel 1 - 20 / 178274  
   
Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.
Nat Cancer
Jayaram A, Rashid M, Reid AHM, Orlando F, Thakali S, Zakka L, Goncalves M, O'Dwyer J, Alifrangis C, Jones R, Pintus E, Needleman S, Bianchini D, Wingate A, Ng K, Linch M, McGovern U, Staffurth J, Crabb SJ, Brock S, Birtle A, Vainauskas O, Leone G, Chiwewe M, Hackshaw A, Lopes A, Wetterskog D, Demichelis F, Attard G.
PMID: 42141175 [PubMed - as supplied by publisher]


A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.
Invest New Drugs
Chandran K, Guo C, Pacey S, Villacampa G, Matthews R, Prout T, Fernandes J, Turner A, Parmar M, Riisnaes R, Ferreira A, Carreira S, Bertan C, Crespo M, Figueiredo I, Yuan W, Bogdan D, Raynaud F, Ruddle R, Calě B, Maddalena M, Calcinotto A, Yap C, Sharp A, Alimonti A, De Bono J, Paschalis A.
PMID: 42141162 [PubMed - as supplied by publisher]


Re: Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
Eur Urol
Compérat E.
PMID: 42140860 [PubMed - as supplied by publisher]


OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial.
Radiother Oncol
Corda H, Blanc-Lapierre A, Pigne G, Cartier L, Pasquier D, Ronchin P, Bera G, Hasbini A, Schipman B, Khalifa J, Sargos P, Quivrin M, Schick U, Mallet F, Laude C, Morand C, Loos G, Vaugier L, Mesgouez-Nebout N, Supiot S.
PMID: 42140755 [PubMed - as supplied by publisher]


Circulating microbial metabolites and the gut-prostate axis in prostate cancer: Implications for laboratory biomarkers and therapeutic response.
Clin Chim Acta
Tan MW, Clister D, Chandra QM, Wangsa CE, Simone CN, Umaya C, Choi J, Park S, Rani A, Akter S, Kim B, Kim SH, de Azambuja Ribeiro RIM, Syahputra RA.
PMID: 42140378 [PubMed - as supplied by publisher]


Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.
J Natl Compr Canc Netw
Flaig TW, Spiess PE, Abern M, An Y, Bangs R, Begovic J, Brown J, Buyyounouski MK, Chan K, Chang P, Chin AI, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kundu S, Lele SM, Luckenbaugh A, Maldonado J, Mei L, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Seyedin S, Siefker-Radtke AO, Stewart T, Sundi D, Swami U, Tollefson M, Wright JL, Cassara CJ, Sliker B.
PMID: 42140269 [PubMed - indexed for MEDLINE]


Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study.
Urol Oncol
Rioja P, Passarella C, Angel M, Valderrama W, Ainaud FB, Anguera G, Gómez V, Ruiz-Granados Á, Plata D, Zapata MI, Orta-Ruiz A, Quiroga MNG, Bourlon MT, Grande E, Ray Manneh Kopp, Molina-Cerrillo J, Maroto P, Sade JP, Castellano D.
PMID: 42139851 [PubMed - as supplied by publisher]


Validation of a large language model as a decision tool for drug interaction in prostate cancer: A comparative study against UpToDate. Meet-URO 5/25 - GENIE study.
J Geriatr Oncol
Rota S, Tozzi AE, Fanelli M, Dri A, Bortolus G, Tortorella A, Zambotti E, Congi R, Pretto G, Serra R, Membrino A, Di Civita M, Cursano MC, Zanardi E, Procopio G, Santini D, Zucali PA, Verzoni E, Gusmaroli E.
PMID: 42139849 [PubMed - as supplied by publisher]


Feasibility of Establishing Community Living Labs (CoLLabs) to Improve Access to Prostate Health Resources, Education, Amenities, and Community Health: Protocol for a Pragmatic Clinical Trial.
JMIR Res Protoc
Odedina FT, Bolajoko O, Wimberly Q, Lee D, Willis F, Moutlrie T, Ford W, Green D, Merriweather A, Turner J, Fudge M.
PMID: 42139705 [PubMed - indexed for MEDLINE]


Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state-of-the-art.
Expert Rev Anticancer Ther
Fahey C, Sud S, Remella A, Milowsky M.
PMID: 42139181 [PubMed - as supplied by publisher]


A Rare Case of Primary Pulmonary Choriocarcinoma Metastasizing to the Kidney: Diagnostic and Therapeutic Complexities.
Cancer Rep (Hoboken)
Belics Z, Fürich A, Bogyó L, Tihanyi H, Madarász M, Rózsa D, Molnár G, Gérecz B, Hupuczi P.
PMID: 42138484 [PubMed - indexed for MEDLINE]


Preliminary results and experiences of fluorescence confocal microscopy using the Histolog® Scanner in prostate cancer diagnostics: a feasibility study.
BJU Int
Meszes-Tóth A, Gyulai AT, Izsák B, Erdélyi AE, Gáti Z, Schönleber J, Tenke P, Köves B.
PMID: 42138307 [PubMed - as supplied by publisher]


Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters.
J Clin Invest
Haddad G, Guo J, Xi Y, Albayrak E, Huseni M, Hamidi H, Banchereau R, Kadel E, Dubey S, Carter C, Kapur P, Brugarolas J, Pedrosa I.
PMID: 42138077 [PubMed - indexed for MEDLINE]


Cardiometabolic comorbidities and prostate cancer risk: evidence from the prostate, lung, colorectal, and ovarian cancer screening trial.
Front Oncol
Zhu Q, Zeng L, Chen M.
PMID: 42137169 [PubMed]


Urine-based PSMA detection for noninvasive prostate cancer diagnosis: recent advances, translational challenges, and future perspectives.
Front Oncol
Jiao Z, Deng C, Hu J, Zhu S.
PMID: 42137166 [PubMed]


Distinct protein and metabolic profiles in patients with advanced clear-cell renal cell carcinoma treated with sunitinib: a study of the Spanish oncology genitourinary group.
Front Oncol
Quintás G, Sanmartín E, Garcia-Gimenez A, Muńoz-Langa J, Collado A, Suárez C, García Del Muro X, Méndez-Vidal MJ, García-Sánchez J, Salvador-Coloma C, Laínez N, Gallardo E, Munárriz J, Vázquez S, Molins C, Font de Mora J, Reynés G.
PMID: 42137158 [PubMed]


Diagnostic utility of Ki-67 proliferation index, PSA, and other immunohistochemical markers in prostatic basal cell carcinoma: A review of 24 cases in the current literature and discussion on current treatment and diagnostics.
Rare Tumors
DeBinya L, Mathesh V, Wang J.
PMID: 42136983 [PubMed]


The evolving role of PSA in prostate cancer screening: revisiting the evidence in the era of personalized medicine.
Adv Lab Med
Filella X.
PMID: 42136976 [PubMed]


Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study.
Front Immunol
Zou XC, Xu LY, Yuan YY, Zhang GY, Huang JB, Zeng T.
PMID: 42136642 [PubMed - indexed for MEDLINE]


MRI Diagnosis of Giant Renal Hamartoma With Renal Venous Tumor Thrombus: Report of One Case and Literature Review.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
Cen WH, Shen J, Xia SS, Li YK, Yang H, Ban Y.
PMID: 42136348 [PubMed - indexed for MEDLINE]


   
   Artikel 1 - 20 / 178274    Seite 1 von 8914  vorhergehende Seite nächste Seite

 
Rect Bottom
Adserver Footer
 

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

 

Übersetzungsproblem?

mehr >>

  Zeitfenster  
   

Sky right 1